3Vaughan MR, Pippin JW, Griffin SV, et al. AtRA induce Podocyte differentiation and alters nephrin and podocin ex- pression in vitro and in vivo [J].Kidney Int, 2005, 65: 133-144.
4Moreno-Mangano V, Mampaso F, Sepulveda-Munoz JC, et al.Retinoids as a potential treatment for experimental puro- mycin-in-duced Nephrosis [J].Br J Pharmrmacol, 2003, 139:823-831.
5XU Q, Lucio-cazana J, Kitamura M, et al.Retinoids in ne- phrology:Promises and pitfalls [J].kidney Int, 2004, 66: 2119-2131.
6Suzuki A, Ito T, Imai E, et al. Retinoids Regulate the Re- pairing process of the podocytes in puromyein Aminonucleo- side-induced Nephrotic Rats [J].J AM Soc Nephrol, 2003, 14:981-991.
5Nishoka H,Kanauchi M, Dohi K. Role of monocyte chemotactic peptide 1 in diabetic ncphropathy[J].Nephron,2001 ;88(2) :189-90.
6Wagner J, Dechow C, Morath C,et al. Retinoic acid reduces glomerular in- jurying at model of gtomerular damage [J].J Am Soc Nephrol,2000 ; 11 (8) :1479-87.
7Geiger B, Ayalon O. Cadherins [J]. Ann Rev Cell Biol, 1992 ; 8:307-32.
8Morrissey J. Angiotensin and gene expression in the kidney[J].Am J kidney Dis, 1998 ;31 : 171-9.
9Sehlondorff D, Nelson PJ,Luckow B,et al. Chemokines and renal disease [J]. Kid Int, 1997 ;51:610-21.
10Matsui T, Y anmgishi S, Ueda S,et al. Tehnisartan, an angiotensin II type 1 receptor blocker,inhibits advanced glyeation end-product (AGE) -induced monocyte chemoatraetant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferatoractivated receptor-gamma activation [J]. J Int Med Res, 2007 ; 35:482- 9.
3Huang ME,Ye YC ,Chen SR,et al. Use of all trans retinoic acid in the treatment of promyelocytic leukemia[ J]. Blood, 1988,72 ( 2 ) : 567-572.
4Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia[ J]. N Engl J Med, 1997,337 ( 15 ) : 1021-1028.
5Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0439 protocol for newly diagnosed acute promyelocytie leukemia: very long-term resuits and role of maintenance [ J]. Blood, 2011, 117 (18): 4716 -4725.
6Gianni M, KoKen MH, Chelbi-Alix MK, et al. Comdined arseni- eaeidand relinoieaeid treatment enhances differentiationandapop2 tosis in arsenic-resistan IVB4 cell[ J]. Blood, 1998,91 ( 11 ) :4300- 4310.
7Guo W, Wang H,Zhao W,et al. Effect of all-trans retino2 ieacidan- darsenie trioxideon tissuefaetor expression of acutepro 2 myelocytic leukemia[J]. Chin Med J(Engl) ,2001,114(1 ) :30-34.
8Kantarjian H, Issa JP, Rosenfeld CS, et al. Deeitabine improves patient outcomes in myelodysplastic syndromes:results of a phase randomized study [ J ]. C ancer,2006,106 ( 8 ) :1794-1803.
9Sekeres MA, List AF, Cuthbertson D,et al. phase I combina- tion trial of lenalidomide and azacitidine in patients with higher- risk myelodysplastic syndromes [ J ] J Clin Oneol, 2010,28 ( 18 ) : 2253 -2258.
10Pendino F, Dudognon C, Delhommeau F, et al. Retinoic acid recep- tor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death [ J ]. Oncogene ,2003,22 ( 57 ) :9142-9150.
